Axsome Therapeutics Inc (AXSM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Axsome Therapeutics Inc (AXSM) has a cash flow conversion efficiency ratio of -0.379x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-20.70 Million) by net assets ($54.59 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Axsome Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Axsome Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Axsome Therapeutics Inc (AXSM) financial obligations for a breakdown of total debt and financial obligations.
Axsome Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Axsome Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
AB SKF (publ)
ST:SKF-B
|
-0.008x |
|
Lupin Limited
NSE:LUPIN
|
0.147x |
|
BUDWEISER BREW.UNSP.ADR/4
F:4BB1
|
N/A |
|
Suzhou TA&A Ultra Clean Technology Co Ltd
SHE:300390
|
0.019x |
|
Dayforce Inc.
NYSE:DAY
|
0.012x |
|
Eurofins Scientific SE
F:ESF0
|
0.073x |
|
JAMES HARDIE INDUST.ADR/1
F:JHA0
|
N/A |
|
Nordex SE
F:NDX1
|
0.492x |
Annual Cash Flow Conversion Efficiency for Axsome Therapeutics Inc (2013–2025)
The table below shows the annual cash flow conversion efficiency of Axsome Therapeutics Inc from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Axsome Therapeutics Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $88.30 Million | $-93.41 Million | -1.058x | +53.03% |
| 2024-12-31 | $57.02 Million | $-128.41 Million | -2.252x | -196.47% |
| 2023-12-31 | $190.98 Million | $-145.08 Million | -0.760x | +28.57% |
| 2022-12-31 | $109.56 Million | $-116.51 Million | -1.063x | +84.64% |
| 2021-12-31 | $15.63 Million | $-108.23 Million | -6.924x | -904.27% |
| 2020-12-31 | $113.79 Million | $-78.46 Million | -0.689x | -165.71% |
| 2019-12-31 | $178.72 Million | $-46.38 Million | -0.259x | +99.19% |
| 2018-12-31 | $937.92K | $-30.05 Million | -32.043x | -1923.55% |
| 2017-12-31 | $16.72 Million | $-26.47 Million | -1.583x | -60.51% |
| 2016-12-31 | $21.57 Million | $-21.28 Million | -0.987x | -515.94% |
| 2015-12-31 | $46.44 Million | $-7.44 Million | -0.160x | -111.16% |
| 2014-12-31 | $-3.20 Million | $-4.60 Million | 1.435x | +78.43% |
| 2013-12-31 | $-2.03 Million | $-1.63 Million | 0.804x | -- |
About Axsome Therapeutics Inc
Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment… Read more